Editas Medicine, Inc.EDITNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -49.03% | +310.40% | +597.47% | +12265.57% | -19.16% |
| Gross Profit Growth | -47.76% | +0.00% | +0.00% | +0.00% | -21.79% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.11% | +1.36% | +2.55% | +9.22% | +7.42% |
| Weighted Average Shares Diluted Growth | +1.11% | +1.36% | +2.55% | +9.22% | +7.42% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +59.67% | +108.16% | +140.98% | +6352.38% | -6.70% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -31.57% | -40.13% | -45.28% | -38.41% | -45.39% |
| Book Value per Share Growth | -61.96% | -79.08% | -91.94% | -92.99% | -81.08% |
| Debt Growth | -27.83% | -8.81% | -45.38% | -48.94% | +118.96% |
| R&D Expense Growth | -28.61% | -43.87% | -69.35% | -58.49% | -145.32% |
| SG&A Expenses Growth | +13.14% | -30.84% | -29.37% | -31.91% | -30.58% |